Skip to main content

Table 1 Association of high protease expression by stromal cells with other prognostic factors

From: The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis

Parameter Cases MMP-14 MMP-2 TIMP-2: stromal cells TIMP-2: cancer cells
   Number Percentage Pos p value Number Pecentage Pos p value Number Percentage Pos p value Number Percentage Pos p value
Age years              
   <50 160 59 36.9 0.034 85 53.1 0.19 58 36.3 0.79 59 36.9 0.14
   ≥50 379 105 27.7   178 47.0   142 37.5   166 43.8  
Tumor size cm              
   <3 297 93 31.3 0.98 146 49.2 0.65 118 39.7 0.14 122 41.1 0.83
   ≥3 207 65 31.4   106 51.2   69 33.3   87 42.0  
Involved lymph nodes              
   0 190 46 24.2   81 42.6   71 37.4   80 42.1  
   1 to 3 166 61 36.7 0.036 93 56.0 0.041 69 41.6 0.29 75 45.2 0.52
   >3 174 54 31.0   84 48.3   58 33.3   68 39.1  
Peritumoral lymphovascular invasion              
   Yes 143 50 35.0 0.15 76 53.1 0.097 50 35.0 0.15 64 44.8 0.027
   No 75 19 25.3   31 41.3   19 25.3   22 29.3  
Histological grade              
   I 54 18 33.3   25 46.3   19 35.2   23 42.6  
   II 277 81 29.2 0.69 133 48.0 0.83 109 39.4 0.59 119 42.9 0.82
   III 197 64 32.5   99 50.3   69 35.0   79 40.1  
Nuclear grade              
   I 94 20 21.3   40 42.6   39 41.5   42 44.7  
   II 307 98 31.9 0.066 158 51.5 0.27 105 34.2 0.22 128 41.7 0.79
   III 127 45 35.4   59 46.5   53 41.7   51 40.2  
Histological type              
   Invasive ductal carcinoma 470 156 33.2 0.0006 238 50.6 0.021 164 34.9 0.003 28 43.1 0.83
   Others 65 8 12.3   23 35.4   35 53.8   196 41.7  
DNA ploidy              
   Diploid 143 37 25.9 0.09 64 44.8 0.18 58 40.6 0.59 60 42.0 0.99
   Non-diploid 332 112 33.7   171 51.5   126 38.0   139 41.9  
Estrogen receptors              
   Negative 143 53 37.1 0.055 76 53.1 0.22 59 41.3 0.25 61 42.7 0.89
   Positive 374 106 28.3   176 47.1   134 35.8   157 42.0  
Progesterone receptors              
   Negative 219 74 33.8 0.21 109 49.8 0.72 88 40.2 0.26 95 43.4 0.60
   Positive 297 85 28.6   143 48.1   105 35.4   122 41.1  
HER-2/neu expression              
   Negative 437 121 27.7 0.0042 204 46.7 0.042 158 36.2 0.34 179 41.0 0.45
   Positive 102 43 42.2   59 57.8   42 41.2   46 45.1  
p53              
   Negative 374 107 28.6 0.12 186 49.7 0.53 132 35.3 0.24 149 39.8 0.30
   Positive 152 54 35.5   71 46.7   62 40.8   68 44.7  
HSP-27              
   Negative 204 61 29.9 0.097 97 47.5 0.02 63 30.9 0.0024 70 34.3 0.0003
   Positive 157 60 38.2   94 59.9   73 46.5   84 53.5  
Cathepsin D cancer cells              
   Negative 324 94 29.0 0.29 151 46.6 0.21 111 34.3 0.071 127 39.2 0.102
   Positive 207 69 33.3   87 52.2   87 42.0   96 46.4  
Cathepsin D stromal cells              
   Negative 303 78 25.7 0.0035 130 42.9 0.0013 106 35.0 0.21 116 38.3 0.047
   Positive 226 85 37.6   129 57.1   91 40.3   106 46.9  
MMP-11              
   Negative 215 32 14.9 <0.0001 65 30.2 <0.0001 76 35.3 0.46 93 43.3 0.60
   Positive 322 132 41.0   198 61.5   124 38.5   132 41.0  
MMP-2              
   Negative 276 41 14.9 <0.0001 - -   89 32.2 0.017 110 39.9 0.36
   Positive 263 123 46.8   - -   111 42.2   115 43.7  
uPA              
   Negative 374 81 21.7 <0.0001 147 39.3 <0.0001 127 34.0 0.016 143 38.2 0.017
   Positive 160 81 50.6   115 71.9   72 45.4   79 49.4  
  1. HSP, heat-shock protein; MMP, matrix metalloproteinase; Pos, positive; TIMP, tissue inhibitor of metalloproteases; uPA, urokinase-type plasminogen activator.